Free Trial
LON:GENF

Genflow Biosciences Interim Earnings Results & Report

Genflow Biosciences logo
GBX 1.78 -0.02 (-1.28%)
As of 11:39 AM Eastern

Genflow Biosciences reported Interim earnings on September 29, 2026. The company reported EPS of -GBX 0.08.

Earnings Announcement Details

Quarter
Interim
Time
Before Market Opens

Genflow Biosciences EPS Results

Actual EPS
-GBX 0.08
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Genflow Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Genflow Biosciences Interim Earnings FAQ

Genflow Biosciences (LON:GENF) reported earnings of -GBX 0.08 per share for Interim. The report was announced on Tuesday, September 29, 2026.

Genflow Biosciences Earnings Headlines

SIRT6 gene therapy shows promise in aged dogs - ICYMI
Federal Reserve Reveals Disturbing New Plan To Control Your Money
Docket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on page 84 is a plan that could expand oversight of checking accounts, purchases, and money transfers across the country. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what this document means and why it could roll out as soon as this summer.tc pixel
See More Genflow Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Genflow Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Genflow Biosciences and other key companies, straight to your email.

About Genflow Biosciences

Genflow Biosciences (LON:GENF) is a UK based biotech company with R&D facilities in Belgium and a US office in Cambridge, MA, driven by one mission: to deliver therapeutics that potentially halt or slow the ageing process in humans and dogs. The company’s lead compound works through the delivery of a centenarian variant of the SIRT6 gene and has yielded promising preclinical results.

View Genflow Biosciences Profile